Simnova Bio Announces 13,000-Square-Meter Cell Therapy Industrialization Base in Jiangbei New Area

Feb 28, 2024 08:39 CST Updated 08:39

Simnova

Innovative Cell Therapy Product Developer

On February 26, the signing ceremony for the industrialization base project of Simnova's innovative cell therapy drugs was held at the Biopharmaceutical Valley in Jiangbei New Area. Lu Weidong, member of the Standing Committee of the Municipal Party Committee and Secretary of the Jiangbei New Area Working Committee, and Ren Jinsheng, Chairman and CEO of Simcere Pharma, attended the ceremony. Wang Wei, member of the Jiangbei New Area Working Committee and Deputy Director of the Management Committee, presided over the ceremony.

According to reports,Simnova Invests in the Construction of a Cell Therapy Drug Industrialization Base in Jiangbei New AreaThe entire project covers an area of approximately 13,000 square meters and will be used for the industrialization of Simnova's independently developed universal CAR-NK cell therapy products and BiTE CAR-T cell therapy products. The project will drive the development of related industries such as biological enzymes, reagents, and pharmaceutical raw materials, promoting the agglomeration of the biopharmaceutical industry in the New Area.

Lu Weidong stated in his speech that the biopharmaceuticals industry is a strategic emerging industry related to the national economy, people's livelihood, and national security. President Xi Jinping emphasized that we must firmly grasp the lifeline of the development of the biopharmaceuticals industry in our own hands. In recent years, the New Area has focused on the "3+3+X" modern industry direction, prioritizing the biopharmaceuticals industry as a pillar industry for development. It has preliminarily established a full industrial chain life health innovation system led by the gene and cell industry, with innovative drugs and high-end medical devices forming the manufacturing cluster.

Since the beginning of the year, the New Area has launched "Four Major Actions" based on new development conditions: enterprise service, project construction, research-production integration, and investment attraction. By focusing efforts and integrating resources with solid and pragmatic work, it aims to push all market entities in the New Area to a higher level and achieve better development.The establishment of Simnova's industrialization base in the new district marks not only a deeper collaboration between the new district and Sinopharm, but also a vivid practice of both parties leveraging opportunities, exploring new fields, and creating a new future together. The new district will fully support businesses, provide comprehensive services for project construction, ensure smooth integration of research and production, and build an ecosystem for investment attraction, assisting Sinopharm and Simnova to develop better in the new district. Together, they will make the life health industry a bright business card for high-quality development in the new district.

Lu Weidong said, "I hope entrepreneurs can all see the biopharmaceutical industry in the new district."AggregatedWith a solid foundation and the future trend of development along the Yangtze River, one can feel the vibrant momentum and dynamic growth of the Jiangbei New Area. The New Area will continue to accelerate the construction of transportation infrastructure such as Nanjing North Railway Station and subway lines, continuously enhancing industrial capacity. It will study and grasp the development trends of the biopharmaceuticals industry, focus on the needs of enterprises, entrepreneurs, and researchers, and optimize the business environment. By leveraging its educational resources and innovation advantages, it aims to build a fully integrated ecosystem for the biopharmaceuticals industry that connects academics, research, production, and application. Highlighting youthful energy and international openness, it seeks to attract more young people to pursue their dreams in Jiangbei, enabling high-quality enterprises and young innovators to realize their aspirations and shape the future in the New Area.

Ren Jinsheng stated that Simcere Pharmaceutical has always been rooted in Jiangbei. During its growth, it has received care and support from all levels of departments in the new district and has also witnessed and participated in the development process of the new district. The cooperation between the two parties has a long history and a solid foundation. As an affiliate of Simcere Pharmaceutical, the industrialization base of Simnova landing in the new district is precisely a practical measure for Simcere to lay out a modern industrial system in the new district with concrete actions once again. Going forward, Simcere will continue to adhere to long-termism, steadily advance innovation transformation, increase R&D investment, improve management upgrades, and achieve common development and shared prosperity with Jiangbei New District.

Simnova is a company dedicated to bringing innovative cell therapy products to cancer patients.An important affiliate of Simnova,With R&D teams in both Shanghai and BostonThe technological advantage lies in the self-developed universal CAR-NK and BiTE CAR-T technology platforms.Currently, multiple projects in the company's R&D pipeline have entered the clinical stage, particularly in the development of universal cell therapy products for hematological tumors and autoimmune diseases, which are at the forefront in China.

Source | General Department, Life Health Office, Simnova

E.N.D

Previous article recommendations:

First AAV Gene Therapy for Hemophilia A Falls Far Short of Sales Expectations Last Year

Zhong Miao Medical is about to launch a gene therapy clinical trial for advanced retinitis pigmentosa.

Hundreds of Millions in Subsidies and Incentives! Covering Gene Therapy, Cell Therapy, Antibody-Drug Conjugates, Recombinant Proteins, and Peptide Drugs—Beijing's Haidian District Releases Several Measures to Promote High-Quality Development of the Pharmaceutical and Health Industry

Another CRO Company Initiates IPO Process

Simnova Raises Over 300 Million RMB in Financing, Accelerating CGT Global Expansion

The First AAV Gene Therapy Using a Two-Plasmid Packaging System: Genevector's Lead Pipeline Receives IND Approval

Investing 5.01 billion yuan, Orient AMC and Guofeng Investment establish biotechnology fund

Huadao Biologics Completes D+1 Round of Financing

Gracell Bio Announces Official Merger into AstraZeneca Group

The Death of Jesse Gelsinger

Xiong'an Officially Issues! Support for the Development of Modern Life Sciences and Biotechnology Industries such as Cell Therapy, Genetic Engineering, and Tissue Engineering

Competitive Landscape of TIL Cell Therapy in China

Government Invests 6 Billion Yuan to Fund the Establishment of a Life Health Research Institute, Focusing on Cutting-edge Topics like Cell and Gene Therapy

NVIDIA CEO Jensen Huang: The Era of Having to Learn Computer Science and Programming is Over, the Next Golden Track is Life Science and Engineering

EU Commission Approves First Gene-Edited Therapy for Marketing

AstraZeneca Invests $300 Million to Build Cell Therapy Factory

First in China: Universal CAR-NK for Treating Systemic Lupus Erythematosus Approved for Clinical Trials

World's First AAV Gene Therapy for Autism Approved for Clinical Trials

Beijing to Focus on Cell and Gene Therapy, Synthetic Biology Manufacturing as Key Tasks for 2024

FDA Releases Guidelines for the Development of Gene-Editing Therapies and CAR-T Therapies (Full Text of Guidelines Attached)

CDE Releases "Technical Guideline for Non-Clinical Research of Human Stem Cell Products"

CRISPR/Cas9 Gene Editing Therapy Receives FDA Approval for Treating β-Thalassemia

Disclaimer: The content is sourced from Nanjing Jiangbei New Area and other places. The content of this article aims at knowledge sharing. All content is for reference only and does not constitute any advice.